On Monday, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) opened higher 1.63% from the last session, before settling in for the closing price of $4.92. Price fluctuations for RXRX have ranged from $3.79 to $12.36 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 90.93% over the past five years. Company’s average yearly earnings per share was noted 15.16% at the time writing. With a float of $310.78 million, this company’s outstanding shares have now reached $399.15 million.
In terms of profitability, gross margin is -0.08%, operating margin of -960.64%, and the pretax margin is -962.73%.
Recursion Pharmaceuticals Inc (RXRX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Recursion Pharmaceuticals Inc is 23.55%, while institutional ownership is 60.52%. The most recent insider transaction that took place on Mar 27 ’25, was worth 836,987. In this transaction Chief Executive Officer of this company sold 138,574 shares at a rate of $6.04, taking the stock ownership to the 1,117,450 shares. Before that another transaction happened on Mar 27 ’25, when Company’s Officer proposed sale 138,574 for $6.04, making the entire transaction worth $836,987.
Recursion Pharmaceuticals Inc (RXRX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 15.16% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.10% during the next five years compared to -35.28% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Check out the current performance indicators for Recursion Pharmaceuticals Inc (RXRX). In the past quarter, the stock posted a quick ratio of 4.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 33.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.78, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.15 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) saw its 5-day average volume 34.84 million, a positive change from its year-to-date volume of 24.0 million. As of the previous 9 days, the stock’s Stochastic %D was 41.92%. Additionally, its Average True Range was 0.43.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 14.12%, which indicates a significant decrease from 45.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 105.15% in the past 14 days, which was lower than the 106.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.87, while its 200-day Moving Average is $6.40. Nevertheless, the first resistance level for the watch stands at $5.11 in the near term. At $5.22, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.36. If the price goes on to break the first support level at $4.86, it is likely to go to the next support level at $4.72. The third support level lies at $4.61 if the price breaches the second support level.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
There are currently 406,495K shares outstanding in the company with a market cap of 2.03 billion. Presently, the company’s annual sales total 58,840 K according to its annual income of -463,660 K. Last quarter, the company’s sales amounted to 14,750 K and its income totaled -202,490 K.
